Skip to content

A clinical trial to study effects of homoeopathic medicine & integrative medicine(homoeopathy and modern medicine) in patients with metabolic syndrome.

A pilot study of metabolic syndrome metasynthesis of holistic medicine(homoeopathy) and integrative medicine. - nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/066492
Enrollment
50
Registered
2024-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension Health Condition 2: E782- Mixed hyperlipidemia Health Condition 3: E660- Obesity due to excess calories Health Condition 4: E781- Pure hyperglyceridemia

Interventions

Intervention1: Homoeopathic medicines, Integrative medicine (modern medicine and homoeopathic medicine.: Homoeopathic medicines- Idividualized homoeopathic medicines for each patients for 6 months and

Sponsors

Metropolitan Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: We will be considering patients who can satisfy any 3 out of these 5 criteria as per The National Cholesterol Education Program: Adult Treatment Panel III(NCEP: ATP III) later modified by American Heart Association(AHA) & National Heart, Lung and Blood Institute(NHLBI- 1)Abdominal obesity- = 102 cm (40 inches) in males and = 88 cm (35 inches) in females. 2)Hypertension- =130 mm Hg systolic blood pressure ; =85 mm Hg diastolic blood pressure or under antihypertensive drug treatment in a patient with a history of hypertension. 3)Hyperglycemia- =100 mg/dL or under drug treatment for elevated glucose. 4)Hypertriglyceridemia- =150 mg/dL (1.7mmol/ L) or under drug treatment for elevated triglycerides. 5)Low high density lipoprotien cholesterol levels- less than 40 mg/dL in males and less then 50 mg/dL in females or under drug treatment for reduced HDL-C levels

Exclusion criteria

Exclusion criteria: 1) Patients suffering from AIDS, cancer along with metabolic syndrome are excluded. 2)Pregnant & lactating women are excluded. 3)Patients with life threatening diagnosed heart and neurological disorders.

Design outcomes

Primary

MeasureTime frame
Waist circumference- = 102 cm (40 inches) in males and =88 cm (35 inches) in females. Hypertension- = 130/85 mm of hg Blood sugar level- Fasting glucose test or HbA1C test or Oral Glucose Tolerance Test. Triglyceride level- Triglycerides test (TGL) or Lipid profile test. Low HDL-C level- High Density lipoprotein Cholesterol test(HDL-C test) or Lipid profile test. Timepoint: 6 months

Secondary

MeasureTime frame
Waist circumference- = 102 cm (40 inches) in males and =88 cm (35 inches) in females. Hypertension- = 130/85 mm of hg Blood sugar level- Fasting glucose test or HbA1C test or Oral Glucose Tolerance Test. Triglyceride level- Triglycerides test (TGL) or Lipid profile test. High Density lipoprotein Cholesterol level- High Density lipoprotein Cholesterol test(HDL-C test) or Lipid profile test. Timepoint: waist circumference and hypertension measured within every 2 weeks for 6 months. Blood sugar level, Triglyceride level, High Density lipoprotein Cholesterol will be done twice, before administration of medicine and at the end of 6 months

Countries

India

Contacts

Public ContactProf Dr Chandra Nath Das

Metropolitan Homeopathic Medical College and Hospital

ankushsingha35@gmail.com9433536167

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026